December 2024

BNT324/DB-1311 showed encouraging antitumor activity and a manageable safety profile in a Phase 1/2a clinical trial in heavily pretreated patients with locally advanced or metastatic solid tumors, including small cell lung cancer (“SCLC”), non-small cell lung cancer (“NSCLC”)

NEW YORK, Dec. 5, 2024 /PRNewswire/ — PEI Global Partners (“PEI”) is pleased to announce that Project Trident has been awarded the prestigious “Power & Transmission Acquisition of the Year – North America” honor at the IJInvestor Awards 2024. The IJInvestor Awards

SD Biosensor strengthens its new product lineup with the POC molecular diagnostic platform M10 Early detection of patients is expected to contribute to the eradication of tuberculosis in high-risk Asian countries SEOUL, South Korea, Dec. 6, 2024 /PRNewswire/ — SD Biosensor, Inc. (KQ137310), S

Magazine made for you.

Featured:

No posts were found for provided query parameters.

Elsewhere: